To review the structure and physiologic function of liipoprotein(a) [Lp(a)], review the association of Lp(a) with the development of atherosclerosis, and to critically evaluate the current literature regarding the effects of lipid-lowering drug therapy on Lp(a) serum concentrations.
DATA SOURCES:
English language clinical and animal studies, abstracts, and review articles pertaining to Lp(a).
STUDY SELECTION AND DATA EXTRACTION:
Relevant human and animal studies examining Lp(a)'s role in atherosclerosis and the effect of drug therapy on Lp(a) serum concentrations.
DATA SYNTHESIS:
Possible physiologic functions and potential atherogenic mechanisms of Lp(a) are discussed. Evidence supporting the association of Lp(a) with atherosclerosis is presented. Studies evaluating the effects of lipid-lowering drug therapy on Lp(a) concentrations are reviewed and critiqued.
CONCLUSIONS:
Lp(a) concentrations are correlated with the risk of atherosclerotic vascular disease (AVO) in both animal models and human studies. Drug therapies that have produced a consistent reduction in Lp(a) concentration include niacin alone or in combination with a bile acid sequestrant or neomycin. However, additional, larger studies are needed to evaluate the ability of drug therapies to specifically reduce elevated Lp(a) concentrations. Preliminary information suggests that reduction in Lp(a) concentrations may be associated with atherosclerotic plaque regression. Although drugs are available to lower Lp(a), one cannot conclude that lowering of Lp(a) is warranted until clinical trials demonstrating beneficial effects have been published.
Get full access to this article
View all access options for this article.
References
1.
BergK. A new serum type system in man: The Lp system. Acta Pathol Microbiol Scand1963; 59: 369–82.
2.
ScottJ. Lipoprotein(a): Thrombogenic and atherogenic. BMJ1991; 303: 663–4.
3.
DahlenGHGuytonJRAttarMFarmerJAKautzJAGottoAMJr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation1986; 74: 758–65.
4.
DahlenGBergKGillnasTEricsonC. Lp(a) lipoprotein/pre-betalipoprotein in Swedish middle-aged males and patients with coronary heart disease. Clin Genet1975; 7: 334–41.
5.
KostnerGAvogaroPCazzolatoGMarthEBittolo-BonGQuinciGB. Lipoprotein LP(a) and the risk of myocardial infarction. Atherosclerosis1981; 38: 51–61.
6.
KoltringerPJurgensG. A dominant role of lipoprotein(a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis1985; 58: 187–98.
7.
MbewuADDurringtonPN. Lipoprotein(a): Structure, properties, and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis1990; 85: 1–14.
8.
ZenkerGKoltrongerPBoneGNiedekornKPfeifferKJurgensG. Lipoprotein(a) as a strong indicator of cerebrovascular disease. Stroke1986; 17: 942–5.
9.
HoffHFBeckGJSkibinskiCIJurgensGO'NeilJKramerJSerum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation1988; 77: 1238–44.
10.
RennigerWWendtGGNawrockiPWeiglandH. Beitrag zur Problematik des LP-Systems. Humangenetik1965; 1: 658–67.
BergKDahlenGBorresonAL. Lp(a) phenotypes, other lipoprotein parameters, and family history of coronary heart disease in middle-aged males. Clin Genet1979; 16: 347–52.
13.
Pedro-BotetJSentiMNoguesXRubies-PratJRoquerJD'OlhaberriagueLLipoprotein and apolipoprotein profile in men with ischemic stroke. Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke1992; 23: 1556–62.
14.
LabeurCDe BacquerDDe BackerGVinckeJMuyldermansLVandekerckhoreYPlasma lipoprotein(a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography. Clin Chem1992; 38: 2261–6.
RhoadsGGDahlenGBergKMortonNEDannenbergAL. Lp(a) lipoprotein as a risk factor for myocardial infarctionJAMA1986; 256: 2540–4.
17.
RosengrenAWilhelmsenLErikssonERisenbergBWedelH. Lipoprotein(a) and coronary heart disease: A prospective case-control study in a general population sample of middle-aged men. BMJ1990; 301: 1248–51.
18.
UtermannG. The mysteries of lipoprotein(a). Science1989; 246: 904–10.
19.
LoscalzoJ. Lipoprotein(a): A unique risk factor for atherothrombotic disease. Arteriosclerosis1990; 10: 672–9.
ArmstrongVWCremerPEberleEMankeASchulzeFWielandHThe association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: Dependence on serum LDL levels. Atherosclerosis1986; 62: 249–57.
22.
RaderDJBrewerHB. Lipoprotein(a): Clinical approach to a unique atherogenic lipoprotein. JAMA1992; 267: 1109–12.
HaberlandMEFlessGScanuAMFogelmannAM. Modification of Lp(a) by malondialdehyde leads to avid uptake by human monocyte-macrophages (abstract). Circulation1989; 80 (suppl II):II–163.
25.
MilesLAPlowEF. Lp(a): An interloper in the fibrinolytic system. Thromb Haemost1990; 63: 331–5.
26.
HarpelPCGordonBRParkerTS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA1989; 86: 3847–51.
27.
MilesLAFlessGMLeveinEGScanuAMPlowEF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature1989; 301–3.
28.
HajjarKAGavishDBreslowJLNachmanRL. Lipoprotein (a) modulation of endothelial call surface fibrinolysis and its potential role in atherosclerosis. Nature1989; 339: 303–5.
29.
Gonzalez-GronowMEdelbergJMPizzoSV. Further characterization of the cellular plasminogen binding site. Evidence that plasminogen 2 and lipoprotein a compete for the same site. Biochemistry1989; 28: 2374–7.
30.
LoscalzoJWeinfeldMFlessGMScanuAM. Lipoprotein(a), fibrin binding and plasminogen activation. Arteriosclerosis1990; 10: 240–5.
31.
EatonDLTomlinsonJEHigginsDKoschinskyMLLawnDLZioncheckTF. The effect of recombinant apolipoprotein(a) on in-vitro fibrinolysis (abstract). Fibrinolysis1990; 4: 16.
32.
KaradiIKostnerGMGriesANimpfJRomicsLMalleE. Lipoprotein(a) and plasminogen are immunochemically related. Biochem Bio-phys Acta1988; 960: 91–7.
33.
EdelbergJMGonzalez-GronowMPizzoSV. Lipoprotein(a) inhibits streptokinase-mediated activation of human plasminogen. Biochemistry1989; 28: 2370–4.
34.
EdelbergJMGonzalez-GronowMPizzoSV. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res1990; 57: 155–62.
35.
HalvorsenSSkjonsbergOHBergKGodalHC. Does Lp(a) lipoprotein inhibit the fibrinolytic system?Thromb Res1992; 68: 223–32.
36.
LuHBruckertJSoriaJLiHde GennesJLLegrandAAbsence of lipoprotein (a) inhibition of tPA induced thrombolysis in a patient's plasma milieu. Blood Coagul Fibrinolysis1990; 1: 513–6.
37.
NachmanRLGavishDAzrolanNClarksonTB. Lipoprotein(a) in diet-induced atherosclerosis in nonhuman primates. Arteriosclerosis Thromb1991; 11: 32–8.
38.
RathMNiendorfAReblinTKrebberHJBeisiegelU. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis1989; 9: 579–92.
39.
CushingGLGaubatzJWNavaMLBocanTMAGuytonJRWeilbaecherD. Quantitation and localization of apolipoproteins(a) and B in coronary artery bypass vein grafts resected at re- operation. Arteriosclerosis1989; 9: 593–603.
40.
UtermannGMenzelHJKraftHGDubaHCKemmlerHGSeitzC. Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a)-lipoprotein concentration in plasma. J Clin Invest1987; 80: 458–65.
41.
BrownGAlbersJJFisherSMSchaeferSMLinJTKaplanCRegression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med1990; 323: 1289–98.
42.
AlbersJJMarcovinaSMLodgeMS. The unique lipoprotein(a): Properties and immunochemical measurement. Clin Chem1990; 36: 2019–26.
43.
HellstenGBownmanKHallmansGDahlenG. Lipids and endurance physical activity. Atherosclerosis1989; 75: 93–4.
44.
KostnerGM. The physiologic role of Lp(a). In: ScanuAM, ed. Lipoprotein(a). New York: Academic Press; 1990: 183–204.
45.
KostnerGKleinGKremplerF. Can serum Lp(a) concentrations be lowered by drugs and/or diet? In: CarlsonLAOlssonG, eds. Treatment of hyperlipoproteinemia. New York: Raven, 1984: 151–6.
46.
CarlsonLAHamstenAAsplundA. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med1989; 226: 271–6.
47.
LepreFCampbellBCraneSHickmanP. Low-dose sustained release nicotinic acid (Tri-B3) and lipoprotein (a) (letter). Am J Cardiol1992; 70: 133.
48.
MatsunagaAHandaKMoriTMoriyamaKHidakaKYukiNEffects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia. Atherosclerosis1992; 94: 241–8.
GurakarAHoegJMKostnerGPapadopoulosNMBrewerHBJr. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis1985; 57: 1289–98.
51.
PelegriARomeroRSentiMNoguesXPedro-BotetJRubies-PratJ. Effect of bezafibrate on lipoprotein(a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving hemodialysis. Nephrol Dial Transplant1992; 7: 623–6.
52.
BarbirMHuntBKushwahaSKehelyAPrescotRThompsonGRMaxepa versus bezafibrate in Hyperlipidemic cardiac transplant recipients. Am J Cardiol1992; 70: 1596–601.
53.
BimmermannABoerschmannCSchwartzkopffWVon BaeyerHSchleicherJ. Effective therapeutic measures for reducing lipoprotein(a) in patients with dyslipidemia. Lipoprotein(a) reduction with sustained-release bezafibrate. Curr Ther Res1991; 49: 635–43.
54.
MaggiFMBiasiGMCatapanoAL. Reduction of Lp(a) plasma levels by bezafibrate. Atherosclerosis1993; 100: 127–8.
55.
JauhiainenMKoskineNEhnholmCFrickMHManttariMManninenVLipoprotein(a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis1991; 89: 59–67.
56.
LeitersdorfEEisenbergSEliavOFriedlanderVBerkmanNDannEJGenetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined hypercholesterolemia. Circulation1993; 87 (suppl III):III-35–III-44.
57.
JacobBGRichterWOSchwandtP. Lovastatin, pravastatin and serum lipoprotein(a) (letter). Ann Intern Med1990; 112: 713–4.
58.
LiPKMakTWChiuKMakGYKLeungCBLuiSFEffect of lovastatin on serum lipid profile in the treatment of dyslipoproteinaemia in uraemic patients on continuous ambulatory peritoneal dialysis. Aust N Z J Med1993; 23: 252–7.
59.
FarmerJAWashingtonLCJonesPHShapiroDRGottoAMJrMantellG. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Ther1992; 14: 708–17.
60.
KostnerGMGavishDLeopoldBBolzanoKWeintraubeMSBreslowJL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation1989; 80: 1313–9.
61.
LerenTPHjermannIFossOPLerenPBergK. Long-term effect of lovastatin alone and in combination with cholestyramine on lipoprotein(a) level in familial hypercholesterolemic subjects. Clin Invest1992; 70: 711–8.
62.
TraindlOReadingSFranzMFalgerSKlauserRGisingerJLow-dose lovastatin in hyperlipidemic kidney graft recipients with cyclosporin A. Transplant Proc;1992; 24: 2745–7.
63.
WiklundOAngelinBOlofssonS-EErikssonMFagerGBerglundLApolipoprotein(a) and ischaemic heart disease in familial hypercholesterolemia. Lancet1990; 335: 1360–3.
64.
CobbaertCSergeantPMeyensBSzecsiJKestelootH. Time course of serum Lp(a) in men after coronary artery bypass grafting. Acta Cardiologica1992; 47: 529–42.
65.
UmedaFWatanabeJInoueKHisatomiAMimuraKYamauchiTEffect of pravastatin on serum lipids, apolipoproteins and lipoprotein(a) in patients with non-insulin dependent diabetes mellitus. Endocrinol Jpn1992; 39: 45–50.
66.
FieselerHGArmstrongVWWielandEThieryJSchutzEWalliAKSerum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor pravastatin: Results of a 2-year investigation. Clinica Chimica Acta1991; 204: 291–300.
67.
KlausenICGerdesLUMeinertzHHansenFAFaergemanO. Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolemia treated with bile acid sequestration. Eur J Clin Invest1993; 23: 240–5.
68.
WannerCLubrich-BirknerSummOWeilandHSchollmeyerP. Effect of simvastatin on qualitative and quantitative changes of protein metabolism in CAPD patients. Nephron1992; 62: 40–6.
69.
ThieryJArmstrongVWSchleefJCreutzfeldtCCreutzfeldtWSeidelD. Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor. Klin Wochenschr1988; 66: 462–3.
70.
McDowellIFWSmyeMTrinickTShorttJAArchibaldMPTrimbleERSimvastatin in severe hypercholesterolaemia: A placebo controlled trial. Br J Clin Pharmacol1991; 31: 340–3.
71.
SlungaLJohnsonODahlenGH. Changes in Lp(a) lipoprotein levels during treatment of hypercholesterolemia with simvastatin. Eur J Clin Pharmacol1992; 43: 369–73.
72.
VessbyBKostnerGLithellHThomisJ. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). Atherosclerosis1982; 44: 61–71.
73.
MaedaSOkunoMAbeANomaA. Lack of effect of probucol on serum lipoprotein(a) levels (letter). Atherosclerosis1989; 79: 267–9.
74.
NaruszewiczMSelingerEDufourDDavignonJ. Probucol protects lipoprotein(a) against oxidative modification. Metabolism1992; 41: 1225–8.
75.
TalbertRL. Hyperlipemia. In: DipiroJTTalbertRLHayesPEYeeGCMatzkeGR, eds. Pharmacotherapy: A pathophysiologic approach. New York: Elsevier; 1992: 357–87.
76.
LerenTPHjermannIBergKLerenPFossOPViksmoenL. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis1988; 73: 135–41.
